الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

advanced accelerator applications - edotreotide - neuroendocrine tumors; radionuclide imaging - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. kun radioaktiiviseen merkitsemiseen, jossa gallium - (68ga) kloridi ratkaisu, ratkaisu gallium (68ga) edotreotide saatu on tarkoitettu positroniemissiotomografia (pet) kuvantaminen somatostatiini-reseptorien yliekspressio aikuisille potilaille, joilla on todettu tai epäillään hyvin eriytetty maha-enteropancreatic neuroendokriinisiä kasvaimet (gep-net) paikallistamisen ensisijainen kasvaimia ja niiden etäpesäkkeitä.

الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidien kuvantaminen - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

linde sverige ab - helium, carbon monoxide - lääkkeellinen kaasu, puristettu - 0.28 % - muut diagnostiset aineet

الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

paranova oy - acitretinum - kapseli, kova - 10 mg - asitretiini

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

paranova oy - acitretinum - kapseli, kova - 25 mg - asitretiini

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

teva sweden ab - galantamini hydrobromidum - depotkapseli, kova - 8 mg - galantamiini

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

teva sweden ab - galantamini hydrobromidum - depotkapseli, kova - 16 mg - galantamiini

فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

teva sweden ab - galantamini hydrobromidum - depotkapseli, kova - 24 mg - galantamiini